drugset / Trial / NCT00755534
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
Phase 2
Terminated
68 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II study will evaluate which is the best way to administer cetuximab after recurrence in 1st line irinotecan+bevacizumab based treatment and to obtain results of the efficacy of the oxaliplatin+cetuximab combination as 2nd line treatment.
Timeline
- Start
- 2008-11
- Primary completion
- 2008-11
- Completion
- 2008-11
Outcome
Outcome not reported
Stopped (Enrollment): “Due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |